Sensei Biotherapeutics, Inc. Share Price
Equities
SNSE
US81728A1088
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 USD | +2.94% | +12.79% | +51.73% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 25.57M 2.13B |
---|---|---|---|---|---|
Net income 2024 * | -30M -2.5B | Net income 2025 * | -39M -3.25B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.05
x | P/E ratio 2025 * |
-1.17
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.35% |
1 day | +2.94% | ||
1 week | +12.79% | ||
3 months | +31.09% | ||
6 months | +98.08% | ||
Current year | +51.73% |
Managers | Title | Age | Since |
---|---|---|---|
John Celebi
CEO | Chief Executive Officer | 52 | 01/18/01 |
Erin Colgan
DFI | Director of Finance/CFO | 43 | 01/20/01 |
Chief Tech/Sci/R&D Officer | 51 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Ringo
CHM | Chairman | 78 | 08/22/08 |
John Celebi
CEO | Chief Executive Officer | 52 | 01/18/01 |
Bob Holmen
BRD | Director/Board Member | 60 | 01/17/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.05 | +2.94% | 25 860 |
26/24/26 | 1.02 | +1.99% | 6,161 |
25/24/25 | 1 | +0.85% | 44,885 |
24/24/24 | 0.9917 | -0.60% | 54,563 |
23/24/23 | 0.9977 | +7.18% | 85,180 |
Delayed Quote Nasdaq, April 29, 2024 at 09:34 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.73% | 25.57M | |
-2.66% | 103B | |
+1.89% | 95.28B | |
+1.46% | 22.15B | |
-15.71% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.32% | 16.05B | |
+4.68% | 13.68B | |
+35.33% | 12.17B |
- Stock Market
- Equities
- SNSE Stock